Schizophrenia - Drug Pipeline Landscape, 2023

Schizophrenia - Drug Pipeline Landscape, 2023

Schizophrenia is a serious mental disorder characterized by continuous or relapsing episodes of psychosis. The condition results in hallucinations, delusions, and extremely disordered thinking and behavior that impair daily functioning and are disabling.

The main cause of schizophrenia is not known. The condition may occur due to the interplay of physical trauma, genetic, psychological and environmental factors.

Schizophrenia symptoms are classified as positive, negative, or cognitive. The positive symptoms include delusions, hallucinations, and disorganized thoughts and speech. Negative symptoms include blunted affect, alogia, anhedonia, asociality, avolition, and apathy. Cognitive symptoms are mainly of two types: neurocognition and social cognition. Neurocognition includes impairment in memory, reasoning, problem solving, speed of processing, and auditory perception. The Schizophrenia diagnosis is based on medical history, symptoms, physical and neurological examination, Neuroimaging tests are used to find other causes of headaches which includes MRI and CT scans.

Schizophrenia is diagnosed by ruling out other mental health disorders and determining the diagnosis through a physical exam, imaging studies such as MRIs and CT scans, a psychiatric evaluation, and the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

Schizophrenia treatment involves the use of antipsychotic medications in combination with psychosocial interventions and social supports. Medical treatment includes second-generation antipsychotics, first-generation antipsychotics, and long-acting injectable antipsychotics. Psychosocial interventions in addition to continuing on medication are important, including individual therapy, social skills training, family therapy, vocational rehabilitation, and supported employment.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Schizophrenia treatment such as Aripiprazole, Risperidone, Brilaroxazine, and others. Key players involved in the development of therapies to treat Schizophrenia are Otsuka Pharmaceuticals, Teva Pharmaceuticals, Luye Pharma, F. Hoffmann-La Roche and others. Two drugs are under late-stage filing rejected, 15 drugs are in Phase III clinical trials and 20+ are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. Reviva Pharmaceuticals Holdings Inc expecting topline data of pivotal Phase III RECOVER trial of brilaroxazine in mid-2023. BioXcel Therapeutics is expecting top line pivotal data of Phase III SERENITY III trial in H1 2023. In Nov 2022, Luye Pharma announced that LY03010 has met the expectations end of the Phase III trial.

Report Highlights

Global Insight Service's, Schizophrenia - Drug Pipeline Landscape, 2023 report provides an overview of the Schizophrenia pipeline drugs. This report covers detailed insights on Schizophrenia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Schizophrenia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.